SEER News and Press, Seer Inc. From 09/17/21

The proteomics market size was $21 billion in 2019 and is estimated to increase to $64 billion in 2024 (growing annually at 15%), larger than the genomics market. The company's proteomics diagnostics technology is Proteograph, an integrated solution consisting of consumables, automati...

REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participating virtually in the upcoming Morgan Stanley Global Healthcare Conference. Seer&#...

Image source: The Motley Fool. Seer, Inc. (NASDAQ: SEER) Q2 2021 Earnings Call Aug 12, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Seer, Inc. (SEER) Q2 2021 Earnings Call Transcript

Seer, Inc. (SEER) Q2 2021 Earnings Conference Call August 12, 2021, 4:30 PM ET Company Participants Carrie Mendivil - Investor Relations Omid Farokhzad - Founder, Chairman and CEO Omead Ostadan - President and COO David Horn - Chief Financial Officer Conference Call Participants Doug Schenkel...

REDWOOD CITY, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2021. “I am incredibly proud of our team a...

REDWOOD CITY, Calif. and BEIJING, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has signed an exclusive distribution agreement with Enlight Medical , a leading company ...

ABNB, AQN, COHR, CRCT, DDS, DIS, FFIN, FIGS, GLOB, IGMS, PAGS, PVG, RKT, RSI, SEER, VIAV, WISH, ZIP For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Thursday's close

REDWOOD CITY, Calif., July 13, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the second quarter 2021 after market close on Thursday, August 12, 2021. ...

Seer, Inc. (SEER) believes its state-of-the-art proteomics platform can transform the market in the same manner next-generation sequencing revolutionized genomics. The company’s three-stage commercial rollout is entering its second phase with a broad launch anticipated in early...

Proteomics has the potential to revolutionize medicine in potentially the same way that genomics has. The traditional field looks primed for disruption and that effort could hit critical mass soon. Quantum-Si has set forth a business plan to utilize consumables as the primary driver o...